Stemcell Institute

Basic Information

Stock Code
7096
Industry
Services
Category Detail
Professional Services for Businesses
Prefecture
Tokyo
Establishment Year
August 1999
Listing Year
June 2021
Official Website
https://www.stemcell.co.jp/corporate/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Wolves Hand, Yukaria, Medical Net, Yumir Link, Rebase, Atra Group, Japan Animal Specialty Medical Center, Japan Emergency Assistance, Hyuga Primary Care, Leoclan, CUC

Overview

Stemcell Institute is a specialized service company founded in 1999 that leads in umbilical cord blood storage and regenerative medicine-related technologies.

Current Situation

Stemcell Institute recorded net sales of approximately 1.68 billion yen and operating profit of approximately 380 million yen in the fiscal year ending March 2020, boasting a high market share in the regenerative medicine sector. Its core umbilical cord blood storage business holds about 99% of the domestic private umbilical cord blood bank market and has a stable customer base. It ensures safety through proprietary stem cell processing technology and quality control, with track records of collaboration in clinical trials in the US and Japan. For sustainability, it has high-precision cell storage facilities and ISO certification, striving to support ethical medical research. It actively collaborates with obstetrics departments and medical institutions, supports academic societies, and focuses on industry awareness activities. Moving forward, it will emphasize expansion of mesenchymal stem cell separation and storage services and iPS cell bank construction plans, aiming to enhance competitiveness in the regenerative medicine market. It positions continuous technology development and domestic and international clinical research support as pillars of growth, with expectations for expansion in cutting-edge medical fields responding to an aging society.

Trivia

Interesting Facts

  • Holds approximately 99% share of the private umbilical cord blood bank market.
  • Pioneering presence in Japan for regenerative medicine use of umbilical cord blood.
  • One of the few companies with specified processed cell product manufacturing approval.
  • Important partner in clinical research at Kochi University.
  • Maintains rigorous quality management system with ISO9001 certification.
  • Member of the US Cord Blood Association (CBA) since 2016.
  • Cell storage facilities boast one of the largest scales in Japan.
  • Focuses on personal information protection with Privacy Mark certification.
  • Numerous sponsorships of industry-academia collaboration societies and medical academic conferences.
  • Umbilical cord blood clinical research for cerebral palsy started in 2017.

Hidden Connections

  • Major shareholder relationship with Japan Trim Co., Ltd. enables collaboration in medical equipment field.
  • Established long-term cooperation system with Duke University in the US for regenerative medicine research.
  • Expanded storage business through partnerships with multiple domestic obstetrics and gynecology clinics.
  • Incorporates compliance with Ministry of Health, Labour and Welfare's umbilical cord blood bank regulatory standards into corporate culture.
  • Cutting-edge stem cell research technology based on joint development with universities and research institutes.
  • Deep connections with major societies such as the Japanese Society for Regenerative Medicine.
  • Implements personnel dispatch and training support to regional medical institutions.
  • Proprietary developed cell quality management system is becoming the industry standard.

Future Outlook

Growth Drivers

  • Expansion of regenerative medicine demand accompanying aging society.
  • Expansion of application areas for umbilical cord blood and stem cell technology.
  • Service demand from increasing number of domestic and international clinical trials.
  • Promotion of industry-academia collaboration strengthening and new treatment development.
  • Further expansion of collaboration with medical and research institutions.
  • Market creation from progress in iPS cell research.
  • New developments in mesenchymal stem cell separation and storage services.
  • Differentiation through advanced technology and from competitors.
  • Operational efficiency improvement through digitalization.
  • Improved business reliability through related legal framework development.

Strategic Goals

  • Secure domestic top position through market share maintenance and expansion.
  • Achieve commercialization and expansion of mesenchymal stem cell storage services.
  • Build advanced bio-bank centered on iPS cell bank.
  • Strengthen domestic and international expansion of cell provision services for clinical trials.
  • Achieve world standard safety and reliability through high-quality cell storage.

Business Segments

Umbilical Cord Blood Bank Service

Overview
Specialized service providing integrated collection, processing, and storage of umbilical cord blood for obstetric medical institutions.
Competitiveness
Operates one of the largest storage facilities in Japan with rigorous quality control systems.
Customers
  • Obstetrics and gynecology clinics
  • Hospitals
  • Medical corporations
  • Research institutions
  • Pharmaceutical companies
  • University labs
  • Cell therapy facilities
  • Clinical research institutions
  • Regenerative medicine companies
  • Insurance organizations
Products
  • Umbilical cord blood collection service
  • Stem cell separation processing
  • Long-term storage
  • Clinical trial support
  • Cell quality inspection
  • Stem cell transportation management
  • Ethics review support
  • Cell processing facility usage
  • Regulatory compliance support
  • Information management system

Mesenchymal Stem Cell Separation and Storage

Overview
Supports regenerative medicine development by providing advanced technology for stem cell separation and storage from umbilical cord tissue.
Competitiveness
Operates the only facility in Japan with specified processed cell product manufacturing approval.
Customers
  • Regenerative medicine companies
  • Bio labs
  • University research institutions
  • Pharmaceutical companies
  • Pathology testing facilities
  • Medical institutions
  • Clinical research institutions
  • Cell therapy facilities
  • Public research institutions
  • Medical device development companies
Products
  • Mesenchymal stem cell separation technology
  • Cell quality management service
  • Specified processed cell product manufacturing
  • Long-term cell storage
  • Cell activation protocol
  • Cell inspection and analysis service
  • Stem cell transportation management
  • Technology development support
  • Clinical application consulting
  • Research cell provision

Regenerative Medicine Research and Development Support

Overview
Comprehensive support services for research and development and clinical trials in the regenerative medicine field.
Competitiveness
Established trust in the industry with extensive track record and high technological capabilities.
Customers
  • Pharmaceutical companies
  • Medical device companies
  • University research institutions
  • Venture companies
  • Clinical research organizations
  • Hospital labs
  • Biotechnology companies
  • Medical institutions
  • Government-related organizations
  • Research and development funds
Products
  • Stem cell-related research platform
  • Clinical trial support
  • Regulatory compliance support
  • Technology consulting
  • Patent technology provision
  • Data analysis service
  • Treatment dissemination support
  • Industry-academia collaboration coordination
  • Test material supply
  • Talent development program

Medical Facility Operation and Management

Overview
Deploys management services to improve operational efficiency of medical facilities.
Competitiveness
Achieves advanced quality management with ISO9001 certification.
Customers
  • Medical corporations
  • Clinics
  • Cell processing facilities
  • Research centers
  • Hospitals
  • University-affiliated facilities
  • Pharmaceutical companies
  • Medical institution operators
  • Certified facilities
  • Medical-related audit institutions
Products
  • Cell processing center management
  • Quality assurance system construction
  • Safety management consulting
  • Legal compliance support
  • Operation manual provision
  • Staff training program
  • Material procurement support
  • Traceability management
  • Equipment maintenance support
  • Risk management

Competitive Advantage

Strengths

  • Approximately 99% share of the domestic private umbilical cord blood bank market
  • Advanced stem cell processing technology and quality control
  • Approval for manufacturing specified processed cell products
  • All-weather large-scale storage facilities
  • Track record contributing to domestic and international clinical trials
  • Close collaboration with obstetrics and regenerative medicine societies
  • Strict legal compliance and certification systems
  • Extensive knowledge in stem cell research and development
  • Multi-location deployment for regional support
  • Reliability through Privacy Mark certification

Competitive Advantages

  • One of the largest cell storage facilities in Japan with equipment investments
  • Superiority in clinical research support and manufacturing consignment contracts
  • Advanced separation and storage technology for umbilical cord blood and mesenchymal stem cells
  • Trust from clinical trial track records in both the US and Japan
  • Responsiveness to latest research and development through industry-academia collaboration
  • Established high-quality stem cell quality control and inspection technology
  • Corresponds to wide customer needs with diverse plans
  • Strong network with a wide range of medical and research institutions
  • High safety and social trust maintained through strict regulatory compliance
  • Market superiority from early start in umbilical cord blood bank business

Threats

  • Risk of impact from changes in regenerative medicine regulations
  • Increase in competing bio companies and new entrants
  • Market uncertainty from delays in clinical trial result announcements
  • Revenue pressure from policy changes or insurance system revisions
  • Need to keep up with the pace of technological innovation in stem cell therapy

Innovations

2024: Launch of New Mesenchymal Stem Cell Separation and Storage Service

Overview
Launched high-quality separation and storage service specialized for mesenchymal stem cells derived from umbilical cord tissue.
Impact
Expects sales growth through new market development.

2023: Obtained Approval for Specified Processed Cell Product Manufacturing

Overview
Cell processing center obtained manufacturing approval from the Ministry of Health, Labour and Welfare, strengthening product quality.
Impact
Contributes to improved reliability and business expansion.

2022: Participation in iPS Cell Bank Construction Plan

Overview
Participated in iPS cell-based bio-bank construction plan and promoted technological collaboration.
Impact
Contributes to elevating status in cutting-edge regenerative medicine research.

2021: Advanced Cell Quality Inspection Technology

Overview
Improved stem cell quality inspection capabilities through introduction of latest equipment.
Impact
Significantly enhanced product safety and reliability.

2020: Expansion of Storage Facilities to Improve Capacity

Overview
Completed one of the largest new cell storage facilities in Japan, expanding storage capacity.
Impact
Infrastructure to support maintaining and expanding market share.

Sustainability

  • Quality assurance through ISO9001 certification acquisition and maintenance
  • Strict personal information protection and Privacy Mark acquisition
  • Introduction of state-of-the-art environmentally considerate cell storage technology
  • Enhanced transparency in medical ethics compliance and research support
  • Health promotion support through collaboration with regional medical institutions
  • Reduced environmental impact through energy-saving cell processing
  • Product accident prevention through advanced safety management systems
  • Continuous staff education and improved work environment
  • Promotion of sustainable regenerative medicine dissemination
  • Fulfillment of social responsibility through thorough legal compliance